Treatment of ocular manifestations of Behçet's disease.
Davatchi
F
F
Behçet's Disease Unit, Rheumatology Research Center, Tehran University for Medical Sciences, Shariati Hospital, Tehran, Iran.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology*
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D014409:Tumor Necrosis Factor-alpha